(1) |
Preclinical study of therapeutic gene transfer mediated by various viral vectors: |
 |
We have two main research projects in this field.
One is a murine therapeutic model of tumor vaccine secreting GM-CSF (GVAX) in combination with nonmyeloablative allogeneic HSCT.
The other is a human experimental model of ribozyme technology for inactivation of leukemogenic fusion mRNA such as BCR-ABL.
|
(2) |
Preclinical study of targeted drug delivery using various cell-targeting strategies and novel molecular target agents: |
 |
We are developing various cell-targeting strategies using cytokines,
adhesion molecules as well as monoclonal antibodies.
PEG-liposome has been applied for this purpose.
In addition, we have made two types of cytokine derivatives by genetic engineering for preclinical study.
We are also studying anti-leukemic effects of a novel signal transduction inhibitor and anti-GvHD effects of a novel cytokine synthesis inhibitor for the future clinical trial.
|
(3) |
Analysis of tumor stem cells and search for molecular targets for their elimination: |
 |
Cure of malignant tumors requires eradication of tumor stem cells.
As a representative model for tumor stem cells, we are studying the identification and characterization of leukemia stem cells using cell tracking strategies and flow cytometry.
|
(4) |
Analysis of normal and neoplastic hematopoiesis based on their interaction with microenvironments: |
 |
Not only normal but also neoplastic hematopoiesis can be supported by the specific interaction between stem/progenitor cells and bone marrow microenvironments.
To simulate this cell to cell contact in vitro, we are using a co-culture system in which stem/progenitor cells are overlaid on the layer of hematopoiesis-supporting stroma cells.
This co-culture system is applied for determination of drug sensitivities and gene transfer effects.
|